134 related articles for article (PubMed ID: 19217709)
1. Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.
Duarte ML; de Moraes E; Pontes E; Schluckebier L; de Moraes JL; Hainaut P; Ferreira CG
Cancer Lett; 2009 Jun; 279(1):57-64. PubMed ID: 19217709
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
3. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
[TBL] [Abstract][Full Text] [Related]
4. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
Hu Z; Zeng Q; Zhang B; Liu H; Wang W
Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
[TBL] [Abstract][Full Text] [Related]
5. Proanthocyanidins inhibit in vitro and in vivo growth of human non-small cell lung cancer cells by inhibiting the prostaglandin E(2) and prostaglandin E(2) receptors.
Sharma SD; Meeran SM; Katiyar SK
Mol Cancer Ther; 2010 Mar; 9(3):569-80. PubMed ID: 20145019
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel promotes lung cancer cell apoptosis via MEG3-P53 pathway activation.
Xu J; Su C; Zhao F; Tao J; Hu D; Shi A; Pan J; Zhang Y
Biochem Biophys Res Commun; 2018 Sep; 504(1):123-128. PubMed ID: 30173893
[TBL] [Abstract][Full Text] [Related]
7. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
8. The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells.
Mukhopadhyay P; Ali MA; Nandi A; Carreon P; Choy H; Saha D
Cancer Res; 2006 Feb; 66(3):1758-66. PubMed ID: 16452236
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
10. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
11. COX-2 potentiates cisplatin resistance of non-small cell lung cancer cells by promoting EMT in an AKT signaling pathway-dependent manner.
Jiang GB; Fang HY; Tao DY; Chen XP; Cao FL
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3838-3846. PubMed ID: 31115011
[TBL] [Abstract][Full Text] [Related]
12. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro.
Guntur VP; Waldrep JC; Guo JJ; Selting K; Dhand R
Anticancer Res; 2010 Sep; 30(9):3557-64. PubMed ID: 20944137
[TBL] [Abstract][Full Text] [Related]
13. Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer.
Liu Y; Wu X; Sun Y; Chen F
J Int Med Res; 2011; 39(5):1682-92. PubMed ID: 22117968
[TBL] [Abstract][Full Text] [Related]
14. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
[TBL] [Abstract][Full Text] [Related]
15. Lentivirus-mediated shRNA interference targeting cyclooxygenase-2 inhibits growth of human non-small cell lung cancer.
Li T; Lu J; Zhong Y
J BUON; 2013; 18(4):908-14. PubMed ID: 24344016
[TBL] [Abstract][Full Text] [Related]
16. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
Park SH; Seong MA; Lee HY
Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
[TBL] [Abstract][Full Text] [Related]
17. Metformin-induced chemosensitization to cisplatin depends on P53 status and is inhibited by Jarid1b overexpression in non-small cell lung cancer cells.
Tortelli TC; Tamura RE; de Souza Junqueira M; da Silva Mororó J; Bustos SO; Natalino RJM; Russell S; Désaubry L; Strauss BE; Chammas R
Aging (Albany NY); 2021 Sep; 13(18):21914-21940. PubMed ID: 34528900
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
Xia Y; He Z; Liu B; Wang P; Chen Y
Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
[TBL] [Abstract][Full Text] [Related]
19. Abnormal expression pattern of the ASPP family of proteins in human non-small cell lung cancer and regulatory functions on apoptosis through p53 by iASPP.
Li S; Shi G; Yuan H; Zhou T; Zhang Q; Zhu H; Wang X
Oncol Rep; 2012 Jul; 28(1):133-40. PubMed ID: 22552744
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
Jones NA; Turner J; McIlwrath AJ; Brown R; Dive C
Mol Pharmacol; 1998 May; 53(5):819-26. PubMed ID: 9584207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
